Matches in SemOpenAlex for { <https://semopenalex.org/work/W2998982600> ?p ?o ?g. }
Showing items 1 to 65 of
65
with 100 items per page.
- W2998982600 abstract "ABSTRACT Background Although lung adenocarcinoma harboring activating Epidermal Growth Factor Receptor (EGFR) mutations respond dramatically to reversible EGFR tyrosine kinase inhibitors (TKI), all patients (pts) inevitably develop acquired resistance. Afatinib, an irreversible EGFR-HER2 dual inhibitor, demonstrated some activity in Non-Small-Cell Lung Cancer (NSCLC) pts progressing after at least 3 months of EGFR-TKI therapy. Materials and methods We analyzed 44 advanced lung adenocarcinoma pts resistant to EGFR-TKI according to criteria used in the LUX-Lung 1 trial (Miller VA, Lancet Oncol 2012) and treated with Afatinib at the daily dose of 40-50 mg in three Italian centers. The drug was given as compassionate use. Results Pts included had a median age of 61.6 year, the majority was female (N = 23/52%), never/former smoker (N = 41/93%), with good PS (0-1; N = 37/84%) and pretreated with > 3 therapy lines (N = 36/81%). EGFR status was assessed in all cases and 35 pts (80%) harbored a mutation in exon 18 (N = 3/8.6%), in exon 19 (N = 19/54,3%), in exon 20 (T790M; N = 2/5.7%) and in exon 21 (N = 11/31.4%). Among the 42 pts evaluable for toxicity, 58% had skin rash (G3 = 4.7%) and 18% diarrhea (G3 = 2.3%). Among the 35 pts evaluable for efficacy, response rate (RR) was 11%, disease control rate (RR+ stable disease) was 65%, median progression free-survival and overall survival were 3.5 months and 4.8 months respectively. EGFR resulted mutated in 3 of 4 responders including 1 pt with T790M mutation. In 4 pts in which tumor biopsy was repeated before starting Afatinib therapy only 1 pt had T790M mutation, with no evidence of response. Conclusions In “real life” experience Afatinib showed encouraging activity in pretreated NSCLC with manageable toxicity profile. Disclosure All authors have declared no conflicts of interest." @default.
- W2998982600 created "2020-01-23" @default.
- W2998982600 creator A5000024298 @default.
- W2998982600 creator A5001928949 @default.
- W2998982600 creator A5008403882 @default.
- W2998982600 creator A5021158045 @default.
- W2998982600 creator A5021264126 @default.
- W2998982600 creator A5030643739 @default.
- W2998982600 creator A5034761732 @default.
- W2998982600 creator A5045442138 @default.
- W2998982600 creator A5052032389 @default.
- W2998982600 creator A5063424146 @default.
- W2998982600 date "2012-09-01" @default.
- W2998982600 modified "2023-10-16" @default.
- W2998982600 title "Efficacy of the Irreversible EGFR-HER2 Dual Inhibitor Afatinib in Pretreated Lung Adenocarcinoma" @default.
- W2998982600 doi "https://doi.org/10.1016/s0923-7534(20)33885-0" @default.
- W2998982600 hasPublicationYear "2012" @default.
- W2998982600 type Work @default.
- W2998982600 sameAs 2998982600 @default.
- W2998982600 citedByCount "0" @default.
- W2998982600 crossrefType "journal-article" @default.
- W2998982600 hasAuthorship W2998982600A5000024298 @default.
- W2998982600 hasAuthorship W2998982600A5001928949 @default.
- W2998982600 hasAuthorship W2998982600A5008403882 @default.
- W2998982600 hasAuthorship W2998982600A5021158045 @default.
- W2998982600 hasAuthorship W2998982600A5021264126 @default.
- W2998982600 hasAuthorship W2998982600A5030643739 @default.
- W2998982600 hasAuthorship W2998982600A5034761732 @default.
- W2998982600 hasAuthorship W2998982600A5045442138 @default.
- W2998982600 hasAuthorship W2998982600A5052032389 @default.
- W2998982600 hasAuthorship W2998982600A5063424146 @default.
- W2998982600 hasBestOaLocation W29989826001 @default.
- W2998982600 hasConcept C121608353 @default.
- W2998982600 hasConcept C126322002 @default.
- W2998982600 hasConcept C143998085 @default.
- W2998982600 hasConcept C2776256026 @default.
- W2998982600 hasConcept C2777930144 @default.
- W2998982600 hasConcept C2778570526 @default.
- W2998982600 hasConcept C2778820342 @default.
- W2998982600 hasConcept C2779438470 @default.
- W2998982600 hasConcept C2780580887 @default.
- W2998982600 hasConcept C2780586478 @default.
- W2998982600 hasConcept C2781182431 @default.
- W2998982600 hasConcept C71924100 @default.
- W2998982600 hasConcept C90924648 @default.
- W2998982600 hasConceptScore W2998982600C121608353 @default.
- W2998982600 hasConceptScore W2998982600C126322002 @default.
- W2998982600 hasConceptScore W2998982600C143998085 @default.
- W2998982600 hasConceptScore W2998982600C2776256026 @default.
- W2998982600 hasConceptScore W2998982600C2777930144 @default.
- W2998982600 hasConceptScore W2998982600C2778570526 @default.
- W2998982600 hasConceptScore W2998982600C2778820342 @default.
- W2998982600 hasConceptScore W2998982600C2779438470 @default.
- W2998982600 hasConceptScore W2998982600C2780580887 @default.
- W2998982600 hasConceptScore W2998982600C2780586478 @default.
- W2998982600 hasConceptScore W2998982600C2781182431 @default.
- W2998982600 hasConceptScore W2998982600C71924100 @default.
- W2998982600 hasConceptScore W2998982600C90924648 @default.
- W2998982600 hasLocation W29989826001 @default.
- W2998982600 hasOpenAccess W2998982600 @default.
- W2998982600 hasPrimaryLocation W29989826001 @default.
- W2998982600 isParatext "false" @default.
- W2998982600 isRetracted "false" @default.
- W2998982600 magId "2998982600" @default.
- W2998982600 workType "article" @default.